Maryland Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Maryland Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82	Buy	+1	New	+$72	﹤0.01%	765

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Maryland Capital Advisors's PTCT Position: Q2 2026 in Review

Maryland Capital Advisors opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 1 share worth $82. The stake represents ﹤0.01% of the portfolio and ranks #765 among its holdings.

382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Maryland Capital Advisors held 1 share of PTC Therapeutics worth $82 as of Q2 2026.
PTC Therapeutics was a new Maryland Capital Advisors position in Q2 2026.
PTC Therapeutics made up ﹤0.01% of Maryland Capital Advisors's portfolio in Q2 2026, its #765 holding.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Maryland Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.